natgillin/translations-raw huggingface dataset:
Orodispersible tablets or oral solution may be used as an alternative to Aripiprazole Mylan Pharma tablets for patients who have difficulty swallowing Aripiprazole Mylan Pharma tablets (see section 5.2).
Orodisperzibilne tablete ali peroralna raztopina se lahko uporabijo kot alternativa tabletam Aripiprazol Mylan Pharma pri bolnikih, ki tablete Aripiprazol Mylan Pharma težko pogoltnejo (glejte poglavje 5.2).
Therefore, aripiprazole is not recommended for use in patients below 13 years of age (see sections 4.8 and 5.1).
Uporabe aripiprazola se zato pri bolnikih, mlajših od 13 let, ne priporoča (glejte poglavji 4.8 in 5.1).
Aripiprazole Mylan Pharma contains the active substance aripiprazole and belong to a group of medicines called antipsychotics.
Zdravilo Aripiprazol Mylan Pharma vsebuje zdravilno učinkovino aripiprazol in spada v skupino zdravil, imenovanih antipsihotiki.
Irritability associated with autistic disorder: the safety and efficacy of aripiprazole in children and adolescents aged below 18 years have not yet been established.
Razdražljivost, povezana z avtistično motnjo: varnost in učinkovitost aripiprazola pri otrocih in mladostnikih, mlajših od 18 let, še nista bili dokazani.
• high blood sugar (characterised by symptoms such as excessive thirst, passing of large amounts of urine, increase in appetite and feeling weak) or family history of diabetes
• imate visok krvni sladkor (značilni simptomi so prekomerna žeja, izločanje velikih količin urina, povečanje apetita in šibkost) ali sladkorno bolezen v družini,
Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours after dosing.
Aripiprazol se dobro absorbira in doseže največjo koncentracijo v plazmi v 3 do 5 urah po uporabi.
• SSRI s (such as paroxetine and fluoxetine) used for depression, OCD, panic and anxiety
• SSRI (kot sta paroksetin in fluoksetin) uporabljamo za depresijo, OCD, paniko in anksioznost,
The pharmacokinetics of aripiprazole and dehydro-aripiprazole in paediatric patients 10 to 17 years of age were similar to those in adults after correcting for the differences in body weights.
Farmakokinetika aripiprazola in dehidroaripiprazola pri pediatričnih bolnikih, starih od 10 do 17 let, je po korekciji glede na razliko v telesni masi podobna farmakokinetiki pri odraslih.
After a 13-26 week stabilisation on aripiprazole (2-15 mg/day) patients with a stable response were either maintained on aripiprazole or substituted to placebo for further 16 weeks.
Po 13-26 tednih stabilizacije na aripiprazolu (2-15 mg/dan) so bolniki s stabilnim odzivom nadaljnjih 16 tednov bodisi ostali na aripiprazolu ali pa so prešli na placebo.
Extrapyramidal symptoms were mainly reported during the stabilisation phase in 17% of patients, with tremor accounting for 6.5%.
O ekstrapiramidnih simptomih so poročali predvsem med stabilizacijsko fazo, in sicer pri 17 % bolnikov, od tega je 6,5 % predstavljal tremor.
When seen, it is usually in those with significant risk factors such as history of diabetes, thyroid disorder or pituitary adenoma.
Če se pojavi, se ponavadi pojavi pri bolnikih s pomembnimi dejavniki tveganja, npr. anamnezo diabetesa, motnjami ščitnice ali adenomom hipofize.
Developmental toxicity, including dose-dependent delayed foetal ossification and possible teratogenic effects, were observed in rats at doses resulting in subtherapeutic exposures (based on AUC) and in rabbits at doses resulting in exposures 3 and 11 times the mean steady-state AUC at the maximum recommended clinical dose.
Razvojne toksične učinke, vključno z od odmerka odvisno zapoznelo fetalno osifikacijo in možnimi teratogenimi učinki, so pri podganah opažali v odmerkih, ki so povzročili subterapevtsko izpostavljenost (na podlagi AUC), in pri kuncih v odmerkih, ki so povzročili izpostavljenost 3- in 11kratne srednje AUC v stanju dinamičnega ravnovesja ob največjem priporočenem kliničnem odmerku.
Do not use this medicine after the expiry date which is stated on the blister and on the carton after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in na škatli za oznako ‘'Uporabno do:''/EXP:''.
Following any confirmed or suspected overdose with aripiprazole, close medical supervision and monitoring should continue until the patient recovers.
Po vsakem potrjenem prevelikem odmerjanju ali sumu na preveliko odmerjanje aripiprazola je potreben skrben zdravstveni nadzor in spremljanje, dokler si bolnik ne opomore.
It is important that you carry on taking Aripiprazole Mylan Pharma for as long as your doctor has told you to.
Pomembno je, da zdravljenje z zdravilom Aripiprazol Mylan Pharma nadaljujete tako dolgo, kot vam je svetoval zdravnik.
Four mood stabilizer subgroups were assessed in the randomised phase: aripiprazole + lithium; aripiprazole + valproate; placebo + lithium; placebo + valproate.
V randomizirani fazi so tako ovrednotili štiri podskupine stabilizatorjev razpoloženja: aripiprazol + litij, aripiprazol + valproat, placebo + litij in placebo + valproat.
Aripiprazole also exhibited moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptors.
Aripiprazol je imel tudi zmerno vezavno afiniteto za mesta ponovnega privzema serotonina in nobene opazne afinitete za muskarinske receptorje.
In the paediatric population somnolence and fatigue were observed more frequently in patients with bipolar disorder compared to patients with schizophrenia.
Pri pediatrični populaciji so o somnolenci in utrujenosti poročali pogosteje pri bolnikih z bipolarno motnjo, kot pri bolnikih s shizofrenijo.
• loss of appetite (anorexia),
• izguba apetita (neješčnost),
Urinary incontinence Urinary retention
Bolezni sečil urinska inkontinanca retencija urina
However, elevated creatine phosphokinase and rhabdomyolysis, not necessarily in association with NMS, have also been reported.
Opisana sta tudi zvišanje kreatin-fosfokinaze in rabdomioliza, ne nujno v povezavi z MNS.
Treatment should be initiated at 2 mg (using an appropriate aripiprazole containing medicinal product) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg.
Zdravljenje je treba uvesti v odmerku 2 mg (uporaba primernega zdravila, ki vsebuje aripiprazol), ki ga bolnik jemlje 2 dni, nato pa se odmerek poveča do odmerka 5 mg, ki ga bolnik jemlje še dodatna 2 dni.
These are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive or preoccupation with an increase in sexual thoughts or feelings.
To so imenuje motnja nadzora impulzov, kamor štejemo vedenja, kot so odvisnost od hazardiranja, čezmerno uživanje hrane ali trošenje denarja, nenormalno povečan libido ali preokupacija z mislimi na spolnost ali spolnimi občutki.
In clinical studies, 10-30 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan).
V kliničnih študijah odmerki od 10 do 30 mg aripiprazola na dan niso pomembno vplivali na presnovo substratov CYP2D6 (razmerje dekstrometorfan/3-metoksimorfinan), CYP2C9 (varfarin), CYP2C19 (omeprazol) ali CYP3A4 (dekstrometorfan).
Gender No dosage adjustment is required for female patients as compared to male patients (see section 5.2).
Spol Pri bolnicah v primerjavi z bolniki odmerka ni treba prilagajati (glejte poglavje 5.2).
Patients treated with any antipsychotic, including aripiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8).
Bolnike, ki dobivajo katerikoli antipsihotik, vključno z aripiprazolom, je treba opazovati glede znakov in simptomov hiperglikemije (npr. polidipsije, poliurije, polifagije in šibkosti); bolnike z diabetesom mellitusom ali dejavniki tveganja zanj pa je treba redno nadzirati, da bi odkrili poslabšanje urejenosti glukoze (glejte poglavje 4.8).
However, the concentrations of the sulphate conjugates of hydroxy aripiprazole in human bile at the highest dose proposed, 30 mg per day, were no more than 6 % of the bile concentrations found in the monkeys in the 39-week study and are well below (6 %) their limits of in vitro solubility.
Vendar je bila koncentracija sulfatnih konjugatov hidroksiaripiprazola v človeškem žolču v 39-tedenski raziskavi ob največjem priporočenem odmerku 30 mg na dan le 6 % koncentracije v žolču pri opicah ter je bila bistveno pod mejo (6 %) njihove topnosti in vitro.
• abnormal muscle breakdown which can lead to kidney problems,
• nenormalna razgradnja mišic, ki lahko povzroči težave z ledvicami,
Aripiprazole may cause sleepiness, fall in blood pressure when standing up, dizziness and changes in your ability to move and balance, which may lead to falls.
Aripiprazol lahko povzroči zaspanost, padec krvnega tlaka v stoječem položaju, omotico in spremembe v sposobnosti gibanja in ravnotežja, kar lahko privede do padcev.
Medicines that increase the level of serotonin are typically used in conditions including depression, generalised anxiety disorder, obsessive-compulsive disorder (OCD) and social phobia as well as migraine and pain:
Zdravila, ki povečajo raven serotonina, navadno uporabljamo za bolezni, vključno z depresijo, generalizirano anksiozno motnjo, obsesivno-kompulzivno motnjo (OCD- obsessive compulsive disorder) in socialno fobijo, kot tudi migrene in bolečine:
Pharmathen International S.A Industrial Park Sapes, Rodopi Prefecture, Block No 5, Rodopi 69300,
Pharmathen International S.A Industrial Park Sapes, Rodopi Prefecture, Block No 5,
The safety profile in a 26-week open-label extension trial was similar to that observed in the short-term, placebo-controlled trial.
V 26-tedenskem, odprtem, podaljšanem preskušanju je bil profil varnosti podoben profilu varnosti v kratkotrajnem, s placebo nadzorovanem preskušanju.
Aripiprazole is metabolised by multiple pathways involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes.
Aripiprazol se presnavlja po več poteh, ki vključujejo encime CYP2D6 in CYP3A4, ne pa encimov CYP1A.
If you notice you are gaining weight, develop unusual movements, experience somnolence that interferes with normal daily activities, any difficulty in swallowing or allergic symptoms, please tell your doctor.
Če opazite povečevanje telesne mase, pojav neobičajnih gibov, pretirano zaspanost, ki vpliva na običajne dnevne aktivnosti, težave s požiranjem ali znake alergije, o tem obvestite svojega zdravnika.
• triptans (such as sumatriptan and zolmitripitan) used for treating migraine
• triptane (kot sta sumatriptan in zolmitriptan) uporabljamo za zdravljenje migrene.
• reports of abnormal liver test values,
• primeri nenormalnih izvidov laboratorijskih jetrnih preiskav,
In three placebo-controlled trials (n = 938; mean age: 82.4 years; range: 56-99 years) of aripiprazole in elderly patients with psychosis associated with Alzheimer's disease, patients treated with aripiprazole were at increased risk of death compared to placebo.
V treh s placebom nadzorovanih preskušanjih (n = 938, povprečna starost: 82,4 leta, razpon: 5699 let) aripiprazola pri starejših bolnikih s psihozo, povezano z Alzheimerjevo boleznijo, je bilo tveganje smrti večje pri bolnikih, ki so dobivali aripiprazol, kot pri tistih, ki so dobivali placebo.
Aripiprazole should be used with caution in patients with a family history of QT prolongation (see section 4.8).
Aripiprazol je treba uporabljati previdno pri bolnikih z družinsko anamnezo podaljšanja intervala QT (glejte poglavje 4.8).
Tics associated with Tourette's disorder: the safety and efficacy of aripiprazole in children and adolescents 6 to 18 years of age have not yet been established.
Trzaji, povezani s Tourettovim sindromom: varnost in učinkovitost aripiprazola pri otrocih in mladostnikih, starih od 6 do 18 let, še ni bila dokazana.
In contrast the 95 % confidence interval for the HR in the older subgroup (aripiprazole, n = 69; placebo, n = 36) was 0.242 to 0.879 and hence a treatment effect could be concluded in the older patients.
Nasprotno pa je bil 95 % interval zaupanja za razmerje tveganja pri starejši skupini (aripiprazol, n = 69; placebo, n = 36) 0,242 do 0,879, torej se pri starejših bolnikih lahko naredi sklepe o učinku zdravljenja.
The safety and efficacy of aripiprazole in the treatment of schizophrenia or manic episodes in Bipolar I Disorder in patients aged 65 years and older has not been established.
Varnost in učinkovitost aripiprazola nista ugotovljeni pri zdravljenju shizofrenije ali maničnih epizod pri bipolarni motnji I pri bolnikih, starih 65 let in starejših.
Additionally, aripiprazole and dehydroaripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
Poleg tega aripiprazol in dehidroaripiprazol in vitro nista pokazala potenciala za spreminjanje presnove s CYP1A2.
Although there is no information on the effect of haemodialysis in treating an overdose with aripiprazole, haemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.
O učinku hemodialize pri zdravljenju prevelikega odmerjanja aripiprazola ni podatkov, vendar je malo verjetno, da bi koristila, ker je aripiprazol izrazito vezan na beljakovine v plazmi.
Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.
Zdravilo Aripiprazol Mylan Pharma je indicirano za zdravljenje shizofrenije pri odraslih in mladostnikih, starih 15 let in več.
Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reductions should therefore be applied.
Pričakovati je mogoče, da imajo drugi močni zaviralci CYP2D6, npr. fluoksetin in paroksetin, podobne učinke, zato je treba odmerjanje podobno zmanjšati.
Concomitant administration of aripiprazole and other inducers of CYP3A4 (such as rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John's Wort) may be expected to have similar effects and similar dose increases should therefore be applied.
Pri sočasni uporabi aripiprazola in drugih induktorjev CYP3A4 (npr. rifampicin, rifabutin, fenitoin, fenobarbital, primidon, efavirenz, nevirapin in šentjanževka) je mogoče pričakovati, da imajo drugi podobne učinke, zato je treba odmerjanje podobno zvečati.
Mylan Healthcare Sp. z.o.o.
Polska Mylan Healthcare Sp. z.o.o.
• certain medicines to treat HIV infection (such as efavirenz, nevirapine, and protease inhibitors e.g. indinavir, ritonavir)
• določena zdravila za zdravljenje okužbe s HIV (kot so efavirenz, nevirapin, zaviralci proteaz, npr. indinavir, ritonavir),
Magyarország Mylan EPD Kft Tel: + 36 1 465 2100
Mylan EPD Kft Tel: + 36 1 465 2100
There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder.
Poročali so o agitaciji, hipertoniji, hipotoniji, tremorju, somnolenci, respiratorni stiski in motnjah hranjenja.
Precise risk estimates for hyperglycaemia-related adverse reactions in patients treated with aripiprazole and with other atypical antipsychotics are not available to allow direct comparisons.
Ni natančnih ocen tveganja za hiperglikemične neželene učinke med prejemniki aripiprazola in drugih atipičnih antipsihotikov, ki bi omogočale neposredno primerjavo.
Potential for other medicinal products to affect aripiprazole
Možnost vpliva drugih zdravil na aripiprazol
Taking Aripiprazole Mylan Pharma with some medicines may mean the doctor will need to change your dose of Aripiprazole Mylan Pharma or the other medicines.
Če jemljete zdravilo Aripiprazol Mylan Pharma z nekaterimi drugimi zdravili, bo morda zdravnik moral spremeniti vaš odmerek zdravila Aripiprazol Mylan Pharma ali drugih zdravil.
Aripiprazole is excreted in human milk.
Aripiprazol se izloča v materino mleko.
Newborn infants exposed to antipsychotics (including aripiprazole) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery.
Pri novorojenčkih, ki so bili med tretjim trimesečjem nosečnosti izpostavljeni antipsihotikom (vključno z aripiprazolom), obstaja tveganje za pojav neželenih učinkov, vključno z ekstrapiramidnimi in/ali odtegnitvenimi simptomi, katerih jakost in čas trajanja po porodu sta lahko različna.
The pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be similar in patients with severe renal disease compared to young healthy subjects.
Ugotovljeno je, da so farmakokinetične lastnosti aripiprazola in dehidroaripiprazola pri bolnikih s hudo boleznijo ledvic podobne kot pri mladih zdravih preiskovancih.
Tell your doctor if you experience any of these behaviours; he/she will discuss ways of managing or reducing the symptoms.
Z vami se bo pogovoril o načinih obvladovanja ali zmanjšanja simptomov.
Actual scores in rating scales used as secondary endpoints, including PANSS and the Montgomery-Asberg Depression Rating Scale showed a significant improvement over haloperidol.
Dejanske ocene po ocenjevalnih lestvicah (vključno s PANSS in lestvico ‘Montgomery-Asberg Depression Rating Scale'), ki so predstavljale sekundarne končne točke, so pokazale značilno izboljšanje v primerjavi s haloperidolom.
In a post-hoc analysis, the improvement over placebo was more pronounced in the patients with associated co-morbidity of ADHD compared to the group without ADHD, where there was no difference from placebo.
V post-hoc analizi je bilo izboljšanje glede na placebo izrazitejše pri bolnikih s sočasno diagnozo motnje pomanjkanja pozornosti v primerjavi z bolniki brez te diagnoze, kjer razlike glede na placebo ni bilo.
4.7 Effects on ability to drive and use machines Aripiprazole has minor to moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section 4.8).
Aripiprazol ima blag do zmeren vpliv na sposobnost vožnje in upravljanje s stroji zaradi morebitnega vpliva na živčni sistem in vid, kot je sedacija, somnolenca, sinkopa, zamegljen vid in diplopija (glejte poglavje 4.8).
Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant.
Aripiprazol morate uporabljati previdno pri bolnikih z znano srčnožilno boleznijo (anamnezo miokardnega infarkta ali ishemično boleznijo srca, srčnim popuščanjem ali prevodnimi motnjami), cerebrovaskularno boleznijo ali stanji, ki ustvarjajo nagnjenost k hipotenziji (dehidracija, hipovolemija in zdravljenje z antihipertenzivi) ali hipertenziji, vključno s pospešeno in maligno hipertenzijo.
• speech disorder,
• motnje govora,
Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue.
Distonični simptomi vključujejo: spazem vratnih mišic, ki lahko povzroči stiskanje žrela, težave pri požiranju, težave pri dihanju in/ali protruzijo jezika.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodiumfree'.
Vsebnost natrija To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na tableto, kar v bistvu pomeni ‘'brez natrija''.
At steady state, dehydro-aripiprazole, the active metabolite, represents about 40% of aripiprazole AUC in plasma.
V stanju dinamičnega ravnovesja predstavlja aktivni presnovek dehidroaripiprazol okrog 40 % AUC aripiprazola v plazmi.
Venous thromboembolism (including pulmonary embolism and deep vein thrombosis) Hypertension
Žilne bolezni ortostatska hipotenzija venska tromboembolija (vključno s pljučno embolijo in globoko vensko trombozo) hipertenzija sinkopa
It has been proposed that aripiprazole's efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism of serotonin 5-HT2A receptors.
Učinkovitost aripiprazola pri shizofreniji in bipolarni motnji I je domnevno posledica kombinacije delnega agonizma na dopaminskih receptorjih D2 in serotoninskih receptorjih 5-HT1A ter antagonizma na serotoninskih receptorjih 5-HT2A
Greece or
Grčija ali
• swelling of hands, ankles or feet,
• zatekanje rok, gležnjev ali stopal,
Congenital anomalies have been reported; however, causal relationship with aripiprazole could not be established.
Poročali so o prirojenih anomalijah, vendar pa vzročne povezave z aripiprazolom niso dokazali.
• blood clots, or family history of blood clots, as antipsychotics have been associated with formation of blood clots
• imate krvne strdke ali težave s krvnimi strdki v družini; antipsihotike namreč povezujejo z nastajanjem krvnih strdkov,
Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia).
Klinični znaki MNS-a so hiperpireksija, mišična rigidnost, spremenjeno duševno stanje in znaki avtonomne nestabilnosti (nereden srčni utrip ali krvni tlak, tahikardija, čezmerno znojenje in motnje srčnega ritma).
These included: dose-dependent adrenocortical toxicity (lipofuscin pigment accumulation and/or parenchymal cell loss) in rats after 104 weeks at 20 to 60 mg/kg/day (3 to 10 times the mean steady-state AUC at the maximum recommended human dose) and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at 60 mg/kg/day (10 times the mean steady-state AUC at the maximum recommended human dose).
Med njimi so bili: od odmerka odvisni adrenokortikalni toksični učinki (kopičenje pigmenta lipofuscina in/ali izguba parenhimskih celic) pri podganah po 104 tednih odmerjanja od 20 do 60 mg/kg/dan (od 3- do 10-kratna srednja AUC v stanju dinamičnega ravnovesja ob največjem priporočenem odmerku za človeka) ter zvečana pogostnost adrenokortikalnih karcinomov in kombiniranih adrenokortikalnih adenomov/karcinomov pri podganjih samicah ob odmerjanju 60 mg/kg/dan (10-kratna srednja AUC v stanju dinamičnega ravnovesja ob največjem priporočenem odmerku za človeka).
Aripiprazole was also studied in a placebo-controlled, long-term maintenance trial.
Uporabo aripiprazola so raziskovali tudi v s placebom nadzorovanem preskušanju dolgotrajnega vzdrževalnega zdravljenja.
Hyperglycaemia and diabetes mellitus
Hiperglikemija in diabetes mellitus
Aripiprazole exhibited high binding affinity in vitro for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors and moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha-1 adrenergic and histamine H1 receptors.
In vitro je imel aripiprazol veliko vezavno afiniteto za dopaminske receptorje D2 in D3 in za serotoninske receptorje 5-HT1A in 5-HT2A ter zmerno afiniteto za dopaminske receptorje D4, serotoninske receptorje 5-HT2C in 5-HT7, adrenergične receptorje alfa-1 in histaminske receptorje H1.
Cerebrovascular adverse reactions
Cerebrovaskularni neželeni učinki
Recurrence prevention of manic episodes in Bipolar I Disorder: for preventing recurrence of manic episodes in patients, who have been receiving aripiprazole as monotherapy or combination therapy, continue therapy at the same dose.
Preprečevanje ponovitev maničnih epizod pri bipolarni motnji I: za preprečevanje ponovitev maničnih epizod pri bolnikih, ki so se zdravili z aripiprazolom samostojno ali v sklopu kombiniranega zdravljenja, se zdravljenje nadaljuje z istim odmerkom.